
- /
- Supported exchanges
- / F
Codexis Inc (4QK F) stock market data APIs
Codexis Inc Financial Data Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Codexis Inc data using free add-ons & libraries
Get Codexis Inc Fundamental Data
Codexis Inc Fundamental data includes:
- Net Revenue: 64 446 K
- EBITDA: -45 779 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Codexis Inc News

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
It is a pleasure to report that the Codexis, Inc. (NASDAQ:CDXS) is up 46% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churning. I...


Baillie Gifford Trims Position in Codexis Inc
Overview of Baillie Gifford (Trades, Portfolio)'s Recent Transaction Warning! GuruFocus has detected 6 Warning Signs with CDXS. On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned i...

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Codexis, Inc. Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs REDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -...

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company
Codexis, Inc. (NASDAQ:CDXS) shares have continued their recent momentum with a 41% gain in the last month alone. Unfortunately, the gains of the last month did little to right the losses of the last y...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.